Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | LPL | P06858 | 6/20 | 0.43 |
| ▸ | FBP1 | P09467 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PMM2 | O15305 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430803 | 1.00 | LIPG (0.43) | LIPGLPLFBP1IDO1TDO2 | |
| SCHEMBL22647885 | 0.86 | LIPG (0.53) | LIPGLPLMAPTTDP1ALDH1A1 | |
| SCHEMBL22636619 | 0.81 | CYP11B1 (0.42) | LIPGLPLMAPTTDP1 | |
| SCHEMBL29430793 | 0.81 | CYP11B1 (0.42) | LIPGLPLMAPTTDP1 | |
| SCHEMBL22647925 | 0.79 | LIPG (0.48) | LIPGLPLIDO1TDO2ROCK1 | |
| SCHEMBL20905062 | 0.78 | LIPG (0.50) | LIPGLPLIDO1TDO2ROCK1 | |
| SCHEMBL2489484 | 0.78 | ALDH1A1 (0.56) | LIPGLPLMAPTROCK1TDP1 | |
| SCHEMBL59736 | 0.75 | ATM (0.49) | LIPGLPLMAPTROCK1TDP1 | |
| SCHEMBL22637535 | 0.74 | MAPT (0.39) | LIPGLPLMAPTALDH1A1 | |
| SCHEMBL190588 | 0.74 | TDP1 (0.54) | LIPGLPLMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | LIPG 4649/4885LPL 4757/4885FBP1 1131/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | LIPG 4052/4885LPL 3957/4885FBP1 788/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | LIPG 4579/4885LPL 4728/4885FBP1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.